Table 3.

Effect of radiation oncologist consultation (compared with urologist management alone) on the odds of active treatment (as compared to no treatment) within the year following prostate cancer diagnosis, among a number of clinical relevant subgroups

	Whole cohort		Low-risk prostate cancer (Gleason ≤6, Stage 1, and PSA <10 ng/mL)		Intermediate or high-risk prostate cancer
	Odds ratio	95% CI	Odds ratio	95% CI	Odds ratio	95% CI
Primary analysis
Unmatched cohort	5.72	5.43–6.02	9.98	8.40–11.86	3.86	3.52–4.24
Matched cohort	3.70	3.42–4.01	8.40	6.65–10.62	4.00	3.60–4.44
Subgroup analysis of age and comorbidity
Age <70; comorbidity ≤3	2.87	2.57–3.20	7.21	5.81–8.96	2.16	1.85–2.52
Age <70; comorbidity 4 or 5	3.86	3.23–4.62	10.44	7.6–15.23	2.42	1.91–3.07
Age >70; comorbidity ≤3	16.59	13.73–20.05	30.83	16.65–57.08	13.49	10.95–16.61
Age >70; comorbidity 4 or 5	20.18	16.35–24.89	23.77	11.72–48.21	17.53	13.95–22.02
Subgroup analysis of region of residence
Urban	4.72	4.36–5.12	9.70	8.05–11.69	3.76	3.40–4.15
Rural	6.10	4.87–7.65	12.65	7.83–20.14	4.98	3.75–6.61
Subgroup analysis of patients undergoing initial biopsy at an academic facility
	4.52	3.91–5.24	8.99	6.25–12.94
Subgroup analysis of tumour volume among those with low-risk prostate cancer
Low volume			4.46	2.14–9.31
High volume			4.93	2.07–11.74
Subgroup analysis of patients receiving MDA on the same day
Urologist alone	referent		Referent		Referent
Same-day RadOnc	3.61	2.96–4.39	6.01	4.07–8.87	3.41	2.62–4.43
Asynchronous RadOnc	5.01	4.63–5.42	10.64	8.90–12.72	3.91	3.55–4.31